Immunome, Inc. - Common Stock (NQ:IMNM)

21.82 -0.19 (-0.84%)

Streaming Delayed Price Updated: 9:47 AM EDT, Jul 24, 2026 Add to My Watchlist

Price and Volume

Volume	16,498
Open	22.13
Bid (Size)	21.76 (100)
Ask (Size)	21.90 (100)
Prev. Close	22.01
Today's Range	21.69 - 22.37
52wk Range	8.665 - 27.65
Shares Outstanding	87,012,328
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

July 20, 2026

From Immunome, Inc.

Via Business Wire

What This Immunome Sale Means a Day Before a Big FDA Milestone ↗

July 12, 2026

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.

Via The Motley Fool

Performance

YTD	+4.8%	+4.8%
1 Month	+12.9%	+12.9%
3 Month	-5.1%	-5.1%
6 Month	-15.5%	-15.5%
1 Year	+90.6%	+90.6%

More News

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

July 08, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 07, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

June 11, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 04, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

May 30, 2026

From Immunome, Inc.

Via Business Wire

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

April 29, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

April 21, 2026

From Immunome, Inc.

Via Business Wire

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗

April 04, 2026

Via The Motley Fool

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Immunome, Inc.

Via Business Wire

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

Via The Motley Fool

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 05, 2026

From Immunome, Inc.

Via Business Wire

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Via The Motley Fool

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

March 03, 2026

From Immunome, Inc.

Via Business Wire

Immunome to Present at Upcoming Investor Conferences

February 23, 2026

From Immunome, Inc.

Via Business Wire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

Via The Motley Fool

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

Via The Motley Fool

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Via The Motley Fool

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Via The Motley Fool

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 05, 2026

From Immunome, Inc.

Via Business Wire

Frequently Asked Questions

Is Immunome, Inc. - Common Stock publicly traded?

Yes, Immunome, Inc. - Common Stock is publicly traded.

What exchange does Immunome, Inc. - Common Stock trade on?

Immunome, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immunome, Inc. - Common Stock?

The ticker symbol for Immunome, Inc. - Common Stock is IMNM on the Nasdaq Stock Market

What is the current price of Immunome, Inc. - Common Stock?

The current price of Immunome, Inc. - Common Stock is 21.82

When was Immunome, Inc. - Common Stock last traded?

The last trade of Immunome, Inc. - Common Stock was at 07/24/26 09:47 AM ET

What is the market capitalization of Immunome, Inc. - Common Stock?

The market capitalization of Immunome, Inc. - Common Stock is 1.90B

How many shares of Immunome, Inc. - Common Stock are outstanding?

Immunome, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.